Rate adjustable drug delivery system

• US 6,421,561 B1
• Filed: 07/11/2000
• Issued: 07/16/2002
• Est. Priority Date: 12/30/1999
• Status: Expired due to Term

• Current Assignee: The Tapemark Company
• Original Assignee: Birch Point Medical, Inc.
• Inventors: Morris, Russell L.
• Primary Examiner(s): Bockelman, Mark
• Application Number:
  US09/613,984
• Time in Patent Office: 735 Days
• Field of Search: 604/20, 604/501, 607/149
• US Class Current: 604/20
• CPC Class Codes: A61N 1/0436 Material of the electrode
• CPC Class Codes: A61N 1/044 Shape of the electrode
• CPC Class Codes: A61N 1/0448 Drug reservoir

Abstract

A transdermal iontophoretic therapeutic agent delivery system which is provided with a plurality of self-contained serially connected galvanic sources.

Claims

1. A transdermal iontophoretic therapeutic agent delivery system comprising;

(a) a plurality of self-contained, serially connected galvanic power sources, wherein said plurality of galvanic power sources alone provide the power for the device and the control for the rate and dosage of therapeutic agent delivered;

(b) wherein said plurality of galvanic power sources are unequal in columbic capacity such that at least one of said galvanic power sources is depleted earlier than the others; and

(c) a resistance device connected in parallel with one or more of said plurality of galvanic power sources.

2. An iontophoretic system as in claim 1 wherein one or more of said galvanic power sources are of a coulombic capacity corresponding to a predetermined dosage rating.

3. An iontophoretic system as in claim 1 wherein one or more of said plurality of galvanic power sources has electrodes prepared using screen-printing.

4. A transdermal iontophoretic therapeutic agent delivery system comprising:

(a) a plurality of self-contained, serially connected galvanic power sources, wherein said plurality of galvanic power sources alone provide the power for the device and the control for the rate and dosage of therapeutic agent delivered;

(b) wherein said plurality of galvanic power sources are unequal in columbic capacity such that at least one of said galvanic power sources is depleted earlier than the others; and

(c) wherein a pair of said galvanic power sources are connected in opposed polar relation and connected in parallel with a resistor device such that net iontophoretic delivery current flows to deliver said therapeutic agent only after said source of lower coulombic capacity is depleted.

5. An iontophoretic system as in claim 4 wherein one or more of said galvanic power sources are of a coulombic capacity corresponding to a predetermined dosage rating.

6. An iontophoretic system as in claim 4 wherein one or more of said plurality of galvanic power sources has electrodes prepared using screen-printing.

7. An iontophoretic system for transdermal delivery of a therapeutic agent, comprising

(a) a plurality of galvanic power sources, each containing an oxidizable species and a reducible species, wherein said plurality of galvanic power sources alone provide the power for the device and the control for rate and dosage of therapeutic agent delivered;

(b) wherein at least one of said plurality of galvanic power sources is a therapeutic agent dispensing power source for receiving and dispensing a therapeutic agent further comprising,

(1) an oxidizable species in contact with a first delivery chamber for containing a therapeutic agent,

(2) a reducible species in contact with a second delivery chamber for containing a therapeutic agent;

(c) conductors serially connecting said plurality of galvanic sources such that an overall galvanic potential of said transdermal iontophoretic delivery system is the sum of said galvanic power sources;

(d) wherein said plurality of galvanic power sources includes one or more sources of significantly lower coulombic capacity than at least one other galvanic power source to provide for earlier depletion;

(e) at least one resistor device connected in parallel with one or more of said plurality of serially connected galvanic power sources of unequal coulombic capacity;

(f) wherein a pair of said serially connected galvanic power sources include a therapeutic agent dispensing source and a second source wherein the therapeutic agent dispensing power source has a higher coulombic capacity than said second power source; and

(g) wherein the serially connected therapeutic agent dispensing power source and another galvanic power source are connected in opposed polarity so that there is no net current flow until said second power source is depleted.

8. A delivery system as in claim 7 wherein said oxidizable species in each of said galvanic power sources is the same.

9. A delivery system as in claim 7 wherein said reducible species in each of said galvanic power sources is the same.

10. A delivery system as in claim 7 wherein all said oxidizable species are the same species and all said reducible species are the same species.

11. A delivery system as in claim 7 wherein said control includes the provision of a predetermined charge capacity for at least one of said galvanic power sources based on adjusting the amount of one or both of said oxidizable and said reducible species provided.

12. A delivery system as in claim 7 wherein said oxidizable species is selected from Mg and Zn and said reducible species is AgCl.

13. An iontophoretic system for transdermal delivery of a therapeutic agent, comprising:

(a) a plurality of galvanic power sources, each containing an oxidizable species and a reducible species, wherein said plurality of galvanic power sources alone provide the power for the device and the control for rate and dosage of therapeutic agent delivered

(b) wherein at least one of said plurality of galvanic power sources is a therapeutic agent dispensing power source for receiving and dispensing a therapeutic agent further comprising,

(1) an oxidizable species in contact with a first delivery chamber for containing a therapeutic agent,

(2) a reducible species in contact with a second delivery chamber for containing a therapeutic agent;

(c) conductors serially connecting said plurality galvanic sources that an overall galvanic potential of said transdermal iontophoretic delivery system is the sum of said galvanic power sources; and

(d) switch means for selectively by-passing one or more power sources serially connected with said therapeutic agent dispensing power source to enable a user to select desired delivery potential.

14. A delivery system as in claim 13 wherein said oxidizable species in each of said galvanic power sources is the same.

15. A delivery system as in claim 13 wherein said reducible species in each of said galvanic power sources is the same.

16. A delivery system as in claim 13 wherein all said oxidizable species are the same species and all said reducible species are the same species.

17. A delivery system as in claim 13 wherein said control includes the provision of a predetermined charge capacity for at least one of said galvanic power sources based on adjusting the amount of one or both of said oxidizable and said reducible species provided.

18. A delivery system as in claim 13 wherein said oxidizable species is selected from Mg and Zn and said reducible species is AgCl.